Onderneming Immunovant, Inc. Nasdaq
Aandelen
US45258J2015
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01-06-19 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 04-10-21 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ian Gourley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Maria Alba
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jennifer Moseley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 24-08-20 |
Jay Stout
CTO | Chief Tech/Sci/R&D Officer | 61 | 01-04-23 |
Chief Tech/Sci/R&D Officer | 66 | 01-06-21 | |
Chau Cheng
IRC | Investor Relations Contact | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 18-12-19 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 18-12-19 |
Douglas Hughes
BRD | Director/Board Member | 62 | 18-12-19 |
Atul Pande
BRD | Director/Board Member | 69 | 18-12-19 |
Frank Torti
CHM | Chairman | 45 | 18-12-19 |
Eric Venker
BRD | Director/Board Member | 37 | 18-02-20 |
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01-06-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 146 053 941 | 62 422 461 ( 42,74 %) | 0 | 42,74 % |
Bedrijfsgegevens
Sector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+51,85% | 57,87 mld. | |
+41,42% | 40,25 mld. | |
-5,25% | 39,94 mld. | |
-5,16% | 28,54 mld. | |
+12,79% | 26,4 mld. | |
-20,18% | 19,33 mld. | |
+30,88% | 12,4 mld. | |
+0,61% | 12,23 mld. | |
+25,06% | 12,2 mld. |